Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Slava Stamova

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Oncoimmunology|July 3, 2015
Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trialFriedrich H Schmitz-Winnenthal, Nicolas Hohmann, Andreas G Niethammer, et al.
Journal for Immunotherapy of Cancer|May 23, 2022
Salt-inducible kinase 3 protects tumor cells from cytotoxic T-cell attack by promoting TNF-induced NF-κB activationAntonio Sorrentino, Ayse Nur Menevse, Tillmann Michels, et al.
Oncoimmunology|February 10, 2022
T cell-mediated elimination of cancer cells by blocking CEACAM6-CEACAM1 interactionJessica Pinkert, Hans-Henning Boehm, Mark Trautwein, et al.
Acta Neuropathologica Communications|May 9, 2023
TSPO acts as an immune resistance gene involved in the T cell mediated immune control of glioblastomaAyse N Menevse, Laura-Marie Ammer, Arabel Vollmann-Zwerenz, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Oncoimmunology|July 3, 2015
Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trialFriedrich H Schmitz-Winnenthal, Nicolas Hohmann, Andreas G Niethammer, et al.
Journal for Immunotherapy of Cancer|May 23, 2022
Salt-inducible kinase 3 protects tumor cells from cytotoxic T-cell attack by promoting TNF-induced NF-κB activationAntonio Sorrentino, Ayse Nur Menevse, Tillmann Michels, et al.
Oncoimmunology|February 10, 2022
T cell-mediated elimination of cancer cells by blocking CEACAM6-CEACAM1 interactionJessica Pinkert, Hans-Henning Boehm, Mark Trautwein, et al.
Acta Neuropathologica Communications|May 9, 2023
TSPO acts as an immune resistance gene involved in the T cell mediated immune control of glioblastomaAyse N Menevse, Laura-Marie Ammer, Arabel Vollmann-Zwerenz, et al.
Pageof 3